Cardiotoxic Profile and Arterial Stiffness of Adjuvant Chemotherapy for Colorectal Cancer.
adjuvant chemotherapy
arterial stiffness
colorectal cancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
07
2019
accepted:
03
10
2019
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
epublish
Résumé
Even though new cancer therapies have improved the overall survival, in some cases they have been associated with adverse effects, including increased cardiotoxicity. The purpose of the present study was to assess the cardiovascular effects of adjuvant chemotherapy for colorectal cancer and mainly the impact on arterial stiffness indices. A total of 70 patients with non-metastatic colorectal cancer who were treated either with FOLFOX (n=16) or with XELOX (n=54) adjuvant chemotherapy were included in the study. All patients were subjected to full cardiovascular evaluation at the beginning and the end of chemotherapy. Arterial stiffness was assessed by means of pulse wave velocity (PWV) and augmentation index (Aix) and full laboratory examinations were conducted prior to, and soon after, the termination of chemotherapy. Patients exhibited significantly higher levels of carotid-radial PWV, carotid femoral RWV and Aix post-chemotherapy (p<0.001); these findings remained significant when examined separately in each treatment subgroup (FOLFOX, XELOX). The observed changes were independent of treatment regimen and baseline patient characteristics. Univariate regression analyses showed that baseline PWVc-r and PWVc-f were the only factors associated with PWVc-r and PWVc-f change, while Aix change was independent of its baseline value. There is a clear burden in arterial stiffness indices post-adjuvant chemotherapy for colorectal cancer in both chemotherapy groups. This is a finding of important clinical significance, however more prospective studies are required in order to encode the possible mechanisms involved.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Even though new cancer therapies have improved the overall survival, in some cases they have been associated with adverse effects, including increased cardiotoxicity. The purpose of the present study was to assess the cardiovascular effects of adjuvant chemotherapy for colorectal cancer and mainly the impact on arterial stiffness indices.
MATERIAL AND METHODS
METHODS
A total of 70 patients with non-metastatic colorectal cancer who were treated either with FOLFOX (n=16) or with XELOX (n=54) adjuvant chemotherapy were included in the study. All patients were subjected to full cardiovascular evaluation at the beginning and the end of chemotherapy. Arterial stiffness was assessed by means of pulse wave velocity (PWV) and augmentation index (Aix) and full laboratory examinations were conducted prior to, and soon after, the termination of chemotherapy.
RESULTS
RESULTS
Patients exhibited significantly higher levels of carotid-radial PWV, carotid femoral RWV and Aix post-chemotherapy (p<0.001); these findings remained significant when examined separately in each treatment subgroup (FOLFOX, XELOX). The observed changes were independent of treatment regimen and baseline patient characteristics. Univariate regression analyses showed that baseline PWVc-r and PWVc-f were the only factors associated with PWVc-r and PWVc-f change, while Aix change was independent of its baseline value.
CONCLUSION
CONCLUSIONS
There is a clear burden in arterial stiffness indices post-adjuvant chemotherapy for colorectal cancer in both chemotherapy groups. This is a finding of important clinical significance, however more prospective studies are required in order to encode the possible mechanisms involved.
Identifiants
pubmed: 32104097
doi: 10.2147/CMAR.S223032
pii: 223032
pmc: PMC7025666
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1175-1185Informations de copyright
© 2020 Visvikis et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Gut. 2006 Feb;55(2):285-91
pubmed: 16239255
Cardiovasc Toxicol. 2019 Jul 5;:
pubmed: 31278615
Clin Colorectal Cancer. 2019 Mar;18(1):58-63
pubmed: 30470591
Oncology. 1993 Nov-Dec;50(6):441-4
pubmed: 8233284
Cureus. 2019 Jul 17;11(7):e5162
pubmed: 31528514
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
J Clin Biochem Nutr. 2010 Nov;47(3):261-5
pubmed: 21103036
Artery Res. 2017 Jun;18:81-86
pubmed: 29861794
Hum Exp Toxicol. 2006 Jun;25(6):305-9
pubmed: 16866187
Onco Targets Ther. 2018 Oct 11;11:6785-6793
pubmed: 30349311
Exp Biol Med (Maywood). 2003 Apr;228(4):396-405
pubmed: 12671184
PLoS One. 2013 Sep 20;8(9):e75157
pubmed: 24073244
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Hypertens Res. 2003 Aug;26(8):615-22
pubmed: 14567500
Int J Clin Oncol. 2005 Dec;10(6):441-3
pubmed: 16369751
Mol Cancer Ther. 2006 Dec;5(12):3303-11
pubmed: 17172434
J Hypertens. 2019 Feb;37(2):339-346
pubmed: 30645208
Interv Cardiol. 2019 May 21;14(2):89-94
pubmed: 31178935
J Clin Oncol. 1992 Nov;10(11):1795-801
pubmed: 1403060
Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):1-5
pubmed: 16529545
Am J Epidemiol. 2000 Nov 1;152(9):847-54
pubmed: 11085396
J Hum Hypertens. 2012 Aug;26(8):476-84
pubmed: 21654851